MedTrace Logo

A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

NCT01606397 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-05-25

No results posted yet for this study

Summary

The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes :

* The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses
* How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks
* How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal
* How LY2409021 works when given with metformin
* How daily dosing of LY2409021 affects the cells that produce insulin

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Administered orally (capsule)

DRUG

LY2409021

Administered orally (capsule)

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606397 on ClinicalTrials.gov